AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277 - 300; http://dx.doi.org/10.3322/caac.20073; PMID: 20610543
   PubMed Web of Science ®Google Scholar
• Bell R, Petticrew M, Luengo S, Sheldon TA. Screening for ovarian cancer: a systematic review. Health Technol Assess 1998; 2:i - iv, 1-84; PMID: 9561894
   PubMedGoogle Scholar
• Cannistra SA. Cancer of the ovary. N Engl J Med 1993; 329:1550 - 9; http://dx.doi.org/10.1056/NEJM199311183292108; PMID: 8155119
   PubMed Web of Science ®Google Scholar
• Ma JJ, Chen BL, Xin XY. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 2009; 146:222 - 6; http://dx.doi.org/10.1016/j.ejogrb.2009.06.011; PMID: 19758744
   PubMed Web of Science ®Google Scholar
• Tirrò E, Consoli ML, Massimino M, Manzella L, Frasca F, Sciacca L, et al. Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res 2006; 66:4263 - 72; http://dx.doi.org/10.1158/0008-5472.CAN-05-3248; PMID: 16618750
   PubMed Web of Science ®Google Scholar
• Zhang S, Ding F, Luo A, Chen A, Yu Z, Ren S, et al. XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics. Cancer Biol Ther 2007; 6:973 - 80; PMID: 17611394
   PubMed Web of Science ®Google Scholar
• Li Y, Jian Z, Xia K, Li X, Lv X, Pei H, et al. XIAP is related to the chemoresistance and inhibited its expression by RNA interference sensitize pancreatic carcinoma cells to chemotherapeutics. Pancreas 2006; 32:288 - 96; http://dx.doi.org/10.1097/01.mpa.0000218314.67111.fb; PMID: 16628085
   PubMed Web of Science ®Google Scholar
• Konopleva M, Zhao S, Hu W, Jiang S, Snell V, Weidner D, et al. The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. Br J Haematol 2002; 118:521 - 34; http://dx.doi.org/10.1046/j.1365-2141.2002.03637.x; PMID: 12139741
   PubMed Web of Science ®Google Scholar
• Sapi E, Alvero AB, Chen W, O’Malley D, Hao XY, Dwipoyono B, et al. Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Oncol Res 2004; 14:567 - 78; PMID: 15666998
   PubMed Web of Science ®Google Scholar
• Sasaki H, Sheng Y, Kotsuji F, Tsang BK. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 2000; 60:5659 - 66; PMID: 11059757
   PubMed Web of Science ®Google Scholar
• Williams J, Lucas PC, Griffith KA, Choi M, Fogoros S, Hu YY, et al. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 2005; 96:287 - 95; http://dx.doi.org/10.1016/j.ygyno.2004.10.026; PMID: 15661210
   PubMed Web of Science ®Google Scholar
• Yang X, Xing H, Gao Q, Chen G, Lu Y, Wang S, et al. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells. Gynecol Oncol 2005; 97:413 - 21; http://dx.doi.org/10.1016/j.ygyno.2004.12.055; PMID: 15863139
   PubMed Web of Science ®Google Scholar
• He XP, Ota T, Liu P, Su CQ, Chien J, Shridhar V. Downregulation of HtrA1 promotes resistance to anoikis and peritoneal dissemination of ovarian cancer cells. Cancer Res 2010; 70:3109 - 18; http://dx.doi.org/10.1158/0008-5472.CAN-09-3557; PMID: 20388781
   PubMed Web of Science ®Google Scholar
• Shaw TJ, Lacasse EC, Durkin JP, Vanderhyden BC. Downregulation of XIAP expression in ovarian cancer cells induces cell death in vitro and in vivo. Int J Cancer 2008; 122:1430 - 4; http://dx.doi.org/10.1002/ijc.23278; PMID: 18027851
   PubMed Web of Science ®Google Scholar
• Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102:33 - 42; http://dx.doi.org/10.1016/S0092-8674(00)00008-8; PMID: 10929711
   PubMed Web of Science ®Google Scholar
• Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000; 102:43 - 53; http://dx.doi.org/10.1016/S0092-8674(00)00009-X; PMID: 10929712
   PubMed Web of Science ®Google Scholar
• Hu W, Wang F, Tang J, Liu X, Yuan Z, Nie C, et al. Proapoptotic protein Smac mediates apoptosis in cisplatin-resistant ovarian cancer cells when treated with the anti-tumor agent AT101. J Biol Chem 2012; 287:68 - 80; http://dx.doi.org/10.1074/jbc.M111.271205; PMID: 22052903
   PubMed Web of Science ®Google Scholar
• Petrucci E, Pasquini L, Petronelli A, Saulle E, Mariani G, Riccioni R, et al. A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. Gynecol Oncol 2007; 105:481 - 92; http://dx.doi.org/10.1016/j.ygyno.2007.01.011; PMID: 17292950
   PubMed Web of Science ®Google Scholar
• Cai Q, Sun H, Peng Y, Lu J, Nikolovska-Coleska Z, McEachern D, et al. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem 2011; 54:2714 - 26; http://dx.doi.org/10.1021/jm101505d; PMID: 21443232
   PubMed Web of Science ®Google Scholar
• Probst BL, Liu L, Ramesh V, Li L, Sun H, Minna JD, et al. Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-α-dependent manner. Cell Death Differ 2010; 17:1645 - 54; http://dx.doi.org/10.1038/cdd.2010.44; PMID: 20431601
   PubMed Web of Science ®Google Scholar
• Tong QS, Zheng LD, Wang L, Zeng FQ, Chen FM, Dong JH, et al. Downregulation of XIAP expression induces apoptosis and enhances chemotherapeutic sensitivity in human gastric cancer cells. Cancer Gene Ther 2005; 12:509 - 14; PMID: 15706355
   PubMed Web of Science ®Google Scholar
• Lu J, Bai L, Sun H, Nikolovska-Coleska Z, McEachern D, Qiu S, et al. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res 2008; 68:9384 - 93; http://dx.doi.org/10.1158/0008-5472.CAN-08-2655; PMID: 19010913
   PubMed Web of Science ®Google Scholar
• Mansouri A, Zhang Q, Ridgway LD, Tian L, Claret FX. Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation. Oncol Res 2003; 13:399 - 404; PMID: 12725530
   PubMed Web of Science ®Google Scholar
• Bai Y, Liu YJ, Wang H, Xu Y, Stamenkovic I, Yu Q. Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin. Oncogene 2007; 26:836 - 50; http://dx.doi.org/10.1038/sj.onc.1209849; PMID: 16953231
   PubMed Web of Science ®Google Scholar
• Brunckhorst MK, Wang H, Lu R, Yu Q. Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis. Cancer Res 2010; 70:7283 - 93; http://dx.doi.org/10.1158/0008-5472.CAN-09-4125; PMID: 20823154
   PubMed Web of Science ®Google Scholar
• Lau YK, Murray LB, Houshmandi SS, Xu Y, Gutmann DH, Yu Q. Merlin is a potent inhibitor of glioma growth. Cancer Res 2008; 68:5733 - 42; http://dx.doi.org/10.1158/0008-5472.CAN-08-0190; PMID: 18632626
   PubMed Web of Science ®Google Scholar
• Xu Y, Stamenkovic I, Yu Q. CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res 2010; 70:2455 - 64; http://dx.doi.org/10.1158/0008-5472.CAN-09-2505; PMID: 20197461
   PubMed Web of Science ®Google Scholar